Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Assessment Of Ovarian Reserve With Anti-Mullerian Hormone: A Comparison Of The Predictive Value Of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, Inhibin B, And Age, R. Riggs, Eyup Duran, M. Baker, T. Kimble, E. Hobeika, L. Yin, L. Matos-Bodden, B. Leader, L. Stadtmauer
Assessment Of Ovarian Reserve With Anti-Mullerian Hormone: A Comparison Of The Predictive Value Of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, Inhibin B, And Age, R. Riggs, Eyup Duran, M. Baker, T. Kimble, E. Hobeika, L. Yin, L. Matos-Bodden, B. Leader, L. Stadtmauer
Eyup Hakan Duran
OBJECTIVE: The objective of this study was to evaluate basal anti-Mullerian hormone as a marker for ovarian responsiveness to fertility treatment. STUDY DESIGN: Frozen basal menstrual cycle day 3 serum samples were evaluated retrospectively for anti-Mullerian hormone, inhibin B, and follicle-stimulating hormone levels in 123 in vitro fertilization cycles (93 patients) and compared with in vitro fertilization records. RESULTS: Anti-Mullerian hormone values correlated the best with the number of retrieved oocytes (r = 0.539; P .05), luteinizing hormone (P > .05), and estradiol (r = -0.190; P .05), luteinizing hormone (P > .05), and estradiol (r = -0.190; P .05). Similarly, for …
The Impact Of A Gonadotropin-Releasing Hormone Antagonist On Gonadotropin Ovulation Induction Cycles In Women With Polycystic Ovary Syndrome: A Prospective Randomized Study, L. Stadtmauer, A. Sarhan, Eyup Duran, H. Beydoun, S. Bocca, B. Pultz, S. Oehninger
The Impact Of A Gonadotropin-Releasing Hormone Antagonist On Gonadotropin Ovulation Induction Cycles In Women With Polycystic Ovary Syndrome: A Prospective Randomized Study, L. Stadtmauer, A. Sarhan, Eyup Duran, H. Beydoun, S. Bocca, B. Pultz, S. Oehninger
Eyup Hakan Duran
OBJECTIVE: To evaluate the effect of the gonadotropin-releasing hormone antagonist Ganirelix on gonadotropin ovulation induction (OI) in patients with polycystic ovary syndrome (PCOS). DESIGN: Prospective, randomized, controlled study. SETTING: Academic infertility center. PATIENT(S): Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles. INTERVENTION(S): Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was >/=13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI. MAIN OUTCOME MEASURE(S): Per cycle clinical pregnancy rate (CPR), live-birth rate (LBR), total gonadotropin dose, days of stimulation, serum LH and peak …